TrialThe lancet. HIV2025

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.

Srilatha Edupuganti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.